Athira Pharma, Inc. (NASDAQ:ATHA) Sees Large Decrease in Short Interest

Athira Pharma, Inc. (NASDAQ:ATHA) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,810,000 shares, a decline of 18.5% from the November 15th total of 2,220,000 shares. Based on an average daily trading volume, of 4,750,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 5.1% of the company’s shares are sold short.

Athira Pharma Trading Down 2.5 %

NASDAQ ATHA opened at $0.57 on Monday. The stock has a market cap of $22.04 million, a PE ratio of -0.21 and a beta of 2.99. Athira Pharma has a 12 month low of $0.41 and a 12 month high of $4.30. The company’s 50-day moving average price is $0.58 and its 200-day moving average price is $1.70.

Athira Pharma (NASDAQ:ATHA) last issued its earnings results on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.05. As a group, sell-side analysts forecast that Athira Pharma will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rothschild Investment LLC purchased a new stake in shares of Athira Pharma in the 2nd quarter worth $34,000. American Century Companies Inc. raised its holdings in shares of Athira Pharma by 9.4% in the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock valued at $103,000 after acquiring an additional 3,333 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Athira Pharma by 25.5% in the second quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock valued at $1,458,000 after acquiring an additional 111,759 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Athira Pharma by 3.5% in the second quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock worth $719,000 after acquiring an additional 9,164 shares during the period. Finally, XTX Topco Ltd bought a new position in Athira Pharma during the 2nd quarter worth about $60,000. Institutional investors own 57.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ATHA. Rodman & Renshaw cut shares of Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. Mizuho downgraded shares of Athira Pharma from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $5.00 to $0.50 in a research note on Thursday, September 19th. BTIG Research lowered Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. Finally, JMP Securities downgraded Athira Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 4th.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.